Imperial College London

AstraZeneca completed its clinical program for a new inhaler propellant with 99.9% lower Global Warming Potential (GWP), marking a significant step in reducing the environmental impact of respiratory medicines. This propellant, HFO-1234ze, will be used in Breztri/Trixeo Aerosphere, a COPD therapy, with regulatory filings planned for Europe, the UK, and China by end of 2024. This aligns with AstraZeneca's Ambition Zero Carbon strategy to cut its carbon footprint by 50% by 2030.

Vaping for at least 2 years in young adults led to lower exercise capacity, similar to smoking, with harder breathing, more muscle fatigue, and reduced fitness, according to a study presented at the European Respiratory Society meeting.

AstraZeneca completed clinical studies for a new inhaler propellant, HFO-1234ze, reducing greenhouse gas emissions by 99.9%. Breztri, a COPD therapy, will be the first to transition, with regulatory submissions expected in Europe, the UK, and China by end of 2024. This aligns with AstraZeneca's Ambition Zero Carbon strategy.

AstraZeneca completed studies supporting regulatory filings for Breztri/Trixeo Aerosphere transition to a next-gen propellant with 99.9% lower Global Warming Potential. Breztri, a COPD therapy, will be the first in AstraZeneca's pMDI portfolio to use this propellant, with clinical programs for wider portfolio transition underway. Studies results will be shared with regulatory authorities, with submissions expected in Europe, UK, and China by end of 2024.

NAPIC aims to drive UK's alternative protein sector innovation, supporting plant-based proteins, lab-grown meats, and protein-rich algae. With £15m funding, it unites businesses, researchers, and stakeholders to address food security and sustainability challenges, potentially creating 25,000 jobs by 2035.

Scientists use a food dye to make mouse skin temporarily transparent, allowing observation of organs and blood vessels. The dye, FD&C Yellow No. 5, modifies the refractive index of tissue to match proteins and fats, enhancing light transmission. The process is reversible and could revolutionize biomedical research and healthcare applications.

A common food dye can temporarily make skin, muscle, and connective tissues transparent, revealing internal organs and blood vessels in mice. The dye, when washed off, restores normal skin color. Researchers believe this could lead to non-invasive diagnostic applications in humans.

Foresite Capital closes $900M fund for novel therapeutics and biotech. Marea Therapeutics raises $190M for cholesterol-lowering monoclonal antibody. Santa Ana Bio secures $168M for autoimmune and inflammatory disease treatments. Bright Peak Therapeutics raises $107M for therapeutic cytokine synthesis. Alzheon raises $100M for Alzheimer’s Phase 3 program. Amber Therapeutics closes $100M Series A for neuromodulation therapy for urinary incontinence. iOnctura secures $85.8M for uveal melanoma treatment. Elion Therapeutics raises $81M for invasive fungal infections. Vilya announces $71M Series A for computational drug design. Moleculent AB closes $26M Series A for functional biology platform. Canary Speech secures $13M for AI-powered vocal biomarker technology. Fuse Diagnostics raises $2M for point-of-need pathogen diagnostics. Nuclera awarded $1.4M for eProtein discovery system.